High Oxygen Delivery for Idiopathic Pulmonary Fibrosis
(HOPE-IPF Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
The purpose is to determine if patients with idiopathic pulmonary fibrosis (IPF) taking nintedanib will have improved exercise endurance, breathlessness and quality of life if breathing 60% oxygen compared to standard of care during an 8 week exercise training program.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but you must be on nintedanib to participate. You cannot have used pirfenidone within 4 weeks of screening or prednisone greater than 10 mg/day for more than 2 weeks within 3 months of the first study visit.
Is high oxygen delivery safe for humans?
Supplemental oxygen therapy is generally considered safe for managing low oxygen levels in various lung diseases, including idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease. However, it is important to use it correctly and for the prescribed duration to maximize benefits and minimize risks.12345
How does high oxygen delivery treatment differ for idiopathic pulmonary fibrosis?
High oxygen delivery treatment for idiopathic pulmonary fibrosis (IPF) is unique because it uses high-flow nasal cannula oxygen therapy (HFNC) to potentially improve exercise capacity, unlike standard oxygen therapy which is typically used to manage low oxygen levels. This approach has been shown to improve oxygenation in other respiratory diseases, but its specific impact on exercise performance in IPF patients is still being evaluated.13678
What data supports the effectiveness of the treatment 60% Oxygen, Supplemental Oxygen, Oxygen Therapy for Idiopathic Pulmonary Fibrosis?
Some studies suggest that supplemental oxygen can help improve symptoms and quality of life for patients with pulmonary fibrosis by normalizing oxygen levels in the blood. However, the overall survival benefit and long-term effects are not fully understood, and more research is needed to confirm its effectiveness.12679
Who Is on the Research Team?
Jordan Guenette, PhD
Principal Investigator
St. Paul's Hospital
Chris Ryerson, MD
Principal Investigator
St. Paul's Hospital
Are You a Good Fit for This Trial?
This trial is for adults over 19 with idiopathic pulmonary fibrosis (IPF) who are stable, can walk at least 50 meters in six minutes, and have an oxygen saturation of 92% or higher. They must be on nintedanib treatment and suitable for a lung rehab program. Those with severe lung function loss, recent high-dose steroids use, other significant diseases affecting exercise capacity, or contraindications to nintedanib cannot join.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants undergo an 8-week exercise training program while receiving either 60% oxygen or standard of care
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- 60% Oxygen
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of British Columbia
Lead Sponsor
Boehringer Ingelheim
Industry Sponsor